Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis - PubMed (original) (raw)
Clinical Trial
. 1993 May 6;328(18):1313-6.
doi: 10.1056/NEJM199305063281805.
Affiliations
- PMID: 8385741
- DOI: 10.1056/NEJM199305063281805
Free article
Clinical Trial
Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
F M Giardiello et al. N Engl J Med. 1993.
Free article
Abstract
Background: Familial adenomatous polyposis is an autosomal dominant disorder characterized by the formation of hundreds of colorectal adenomas and eventual colorectal cancer. Administration of the nonsteroidal antiinflammatory drug sulindac has been followed by regression of polyps in patients with this disorder, but no controlled trial of this drug in patients who have not had surgery has been reported.
Methods: We conducted a randomized, double-blind, placebo-controlled study of 22 patients with familial adenomatous polyposis, including 18 who had not undergone colectomy. The patients received sulindac at a dose of 150 mg orally twice a day for nine months or identical-appearing placebo tablets. The number and size of the polyps were evaluated every three months for one year.
Results: A statistically significant decrease in the mean number of polyps and their mean diameter occurred in patients treated with sulindac, as compared with those given placebo. When treatment was stopped at nine months, the number of polyps had decreased to 44 percent of base-line values and the diameter of the polyps to 35 percent of base-line values (P = 0.014 and P < 0.001, respectively, for the comparison with the changes in the group given placebo). No patient had complete resolution of polyps. Three months after treatment with sulindac was stopped, both the number and the size of the polyps increased in sulindac-treated patients but remained significantly lower than the values at base line. No side effects from sulindac were noted.
Conclusions: Sulindac reduces the number and size of colorectal adenomas in patients with familial adenomatous polyposis, but its effect is incomplete, and it is unlikely to replace colectomy as primary therapy.
Similar articles
- Effect of sulindac on small polyps in familial adenomatous polyposis.
Debinski HS, Trojan J, Nugent KP, Spigelman AD, Phillips RK. Debinski HS, et al. Lancet. 1995 Apr 1;345(8953):855-6. Lancet. 1995. PMID: 7898240 Clinical Trial. No abstract available. - Primary chemoprevention of familial adenomatous polyposis with sulindac.
Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD, Piantadosi S, Garrett E, Geiman DE, Hubbard W, Offerhaus GJ, Hamilton SR. Giardiello FM, et al. N Engl J Med. 2002 Apr 4;346(14):1054-9. doi: 10.1056/NEJMoa012015. N Engl J Med. 2002. PMID: 11932472 Free PMC article. Clinical Trial. - Sulindac causes regression of rectal polyps in familial adenomatous polyposis.
Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, Duhamel O, Trousset M, Attali P. Labayle D, et al. Gastroenterology. 1991 Sep;101(3):635-9. doi: 10.1016/0016-5085(91)90519-q. Gastroenterology. 1991. PMID: 1650315 Clinical Trial. - [Role of suindac in the treatment of familial adenomatous polyposis coli].
Landauer S, Halimi C, Caulin C, Bergmann JF. Landauer S, et al. Therapie. 1999 Nov-Dec;54(6):675-82. Therapie. 1999. PMID: 10709439 Review. French. - Sulindac therapy of colorectal polyps in familial adenomatous polyposis.
Tonelli F, Valanzano R, Dolara P. Tonelli F, et al. Dig Dis. 1994 Sep-Oct;12(5):259-64. doi: 10.1159/000171461. Dig Dis. 1994. PMID: 7882547 Review.
Cited by
- Gastrointestinal Malignancy: Genetic Implications to Clinical Applications.
Trembath HE, Yeh JJ, Lopez NE. Trembath HE, et al. Cancer Treat Res. 2024;192:305-418. doi: 10.1007/978-3-031-61238-1_15. Cancer Treat Res. 2024. PMID: 39212927 Review. - Nonsteroidal Anti-inflammatory Drugs for Chemoprevention in Patients With Familial Adenomatous Polyposis: A Systematic Review and Meta-Analysis.
Farooq U, El Alayli A, Duvvuri A, Mansour R, Pasam RT, Malireddy S, Mustafa RA, Bansal A. Farooq U, et al. Gastro Hep Adv. 2023 Jun 10;2(7):1005-1013. doi: 10.1016/j.gastha.2023.05.009. eCollection 2023. Gastro Hep Adv. 2023. PMID: 39130765 Free PMC article. Review. - Bootstrap Approximation of Model Selection Probabilities for Multimodel Inference Frameworks.
Dajles A, Cavanaugh J. Dajles A, et al. Entropy (Basel). 2024 Jul 15;26(7):599. doi: 10.3390/e26070599. Entropy (Basel). 2024. PMID: 39056962 Free PMC article. - Which Drugs are More Effective in Preventing Familial Adenomatous Polyposis Progression based on Network Meta-analysis?
Luo P, Shi W, Cheng X, Yang J, Pei G, Dong J. Luo P, et al. Curr Pharm Des. 2024;30(20):1548-1563. doi: 10.2174/0113816128289465240422074745. Curr Pharm Des. 2024. PMID: 38698755 - Surgical Decision-Making in Familial Adenomatous Polyposis.
Steinberger AE, Westfal ML, Wise PE. Steinberger AE, et al. Clin Colon Rectal Surg. 2023 Aug 10;37(3):191-197. doi: 10.1055/s-0043-1770732. eCollection 2024 May. Clin Colon Rectal Surg. 2023. PMID: 38617844 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources